Adiponectin, type 2 diabetes and cardiovascular risk
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Adiponectin is viewed as an insulin-sensitizing hormone with anti-inflammatory effects. In accordance, plasma adiponectin is decreased in metabolic disorders including type 2 diabetes mellitus (T2DM). However, in spite of the apparently beneficially effects, recent data from large prospective studies have consistently linked high adiponectin levels with increased cardiovascular (CV) disease and mortality, thus questioning the positive view on adiponectin. Accordingly, we investigated the relationship between adiponectin, incident T2DM and subsequently CV events. Methods We prospectively followed 5349 randomly selected men and women from the community, without T2DM or CV disease. Plasma adiponectin was measured at study entry. Median follow-up time was 8.5 years (IQR 8.0-9.1 years). During follow up, 136 participants developed T2DM. Following their diagnosis, 36 of the 136 participants experienced a CV event (myocardial infarction, ischaemic stroke, or CV death). Results Participants with increasing adiponectin had reduced risk of developing T2DM (p Conclusions In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in studies of populations with predominantly T2DM, increased adiponectin was associated with a reduction in cardiovascular disease risk. 87,88”
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 1×
“Estimated glomerular filtration rate (eGFR) was calculated on the basis of serum creatinine, age, and gender using the MDRD formula.(16)”
MethodAdiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Adipokines and Insulin Resistance
Rabe, K., Lehrke, M., Parhofer, K. G., & Broedl, U. C. (2008) · Molecular Medicine · doi:10.2119/2008-00058.rabe · Cited by 808
Adipocytokines and the Metabolic Complications of Obesity
Rasouli, N., & Kern, P. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1613 · Cited by 743
Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Madsen, M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00591-7 · Cited by 460
Di Angelantonio, E., Chowdhury, R., Sarwar, N., Ray, K. K., Gobin, R., Saleheen, D., Thompson, A., Gudnason, V., Sattar, N., & Danesh, J. (2009) · Circulation · doi:10.1161/circulationaha.109.884866 · Cited by 378
Tsukamoto, O., Fujita, M., Kato, M., Yamazaki, S., Asano, Y., Ogai, A., Okazaki, H., Asai, M., Nagamachi, Y., Maeda, N., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.038 · Cited by 254
Cited by
Pan, A., Wang, Y., Talaei, M., Hu, F. B., & Wu, T. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00316-2 · Cited by 551
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Maiorino, M. I., Bellastella, G., Giugliano, D., & Esposito, K. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0872-6 · Cited by 152
“On the other hand, low plasma levels of adiponectin, an adipose tissue-secreted protein which presents anti-inflammatory and anti-atherogenic properties, correlate with a higher risk of incident type 2 diabetes [12], whereas its high concentrations were associated with a lower risk of diabetes and cardiovascular event…”
BackgroundDiabetes and ageing‐induced vascular inflammation
Assar, M. E., Angulo, J., & Rodríguez‐Mañas, L. (2015) · The Journal of Physiology · doi:10.1113/jp270841 · Cited by 152
“2014) while an elevated concentration of the anti-inflammatory adipokine, adiponectin, reduce such risk (Lindberg et al. 2015).”
BackgroundAl-Hamodi, Z. H., Al‐Habori, M., Al‐Meeri, A., & Saif-Ali, R. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-99 · Cited by 158
“A range of prospective studies demonstrated that high levels of circulating adiponectin are associated with low risk of Type 2 DM even after adjustment for multiple factors that could confound this relationship [22-25].”
Background
Metadata
- Authors
- Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., & Mogelvang, R.
- Affiliations
- Bispebjerg Hospital (DK)
- University of Copenhagen (DK)
- Aarhus University (DK)
- Gentofte Hospital (DK)
- Bispebjerg University Hospital, Copenhagen, Denmark
- Corresponding author
- Lindberg, Søren
- ORCID
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-11-21
- Volume
- 22
- Issue
- 3
- Pages
- 276-283
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2138493608
- Cited by
- 66
- References
- 29
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 4 · 2020: 19 · 2019: 2 · 2018: 7 · 2017: 2 · 2016: 7 · 2015: 6 · 2014: 5
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Hjerteforeningen (12-04-R90-A3871-22735)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- adiponectin, type 2 diabetes, cardiovascular risk, cardiovascular events, myocardial infarction, ischemic stroke, cardiovascular mortality, insulin sensitivity, anti-inflammatory activity, incident diabetes risk, plasma adiponectin levels
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Denmark, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Up-Regulation, Chi-Square Distribution, Linear Models, Proportional Hazards Models, Risk Assessment, Adiponectin, Young Adult, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adiponectin, type 2 diabetes and cardiovascular risk. https://app.cochat.ai/papers/10.1177/2047487313514894
- The paper
- Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., & Mogelvang, R. (2015). Adiponectin, type 2 diabetes and cardiovascular risk. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487313514894
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.